Systemic antineoplastic treatment is used in a wide variety of patients with cancer and can be administered forpotentially curative or palliative purposes. Although this treatment has a real benefit, adverse drug reactions in patientswith cancer are still very common, leading to delays in subsequent prescribed cycles, non-adherence to treatment, andadditional healthcare costs for toxicity management. This study aimed to synthesize knowledge about the systemicantineoplastic treatment toxicity profile to be adopted as a parameter for safe prescription. It is intended to obtainevidence that can improve the quality and safety of systemic antineoplastic treatment prescription, in order to provideinformation on treatment toxicity as well as risk management strategies in this context. This is an integrative review carried out in the EMBASE, LILACS, and PubMed databases, from 2015 to 2019. The evaluation of the individualmethodological quality of the primary studies included in the sample was performed using the Joanna Briggs Institute.Eight studies were included, of which 5 addressed adverse events related to systemic antineoplastic treatment,including 4,970 patients treated with immunotherapy, target therapy, and chemotherapy. One study evaluated thesafety of prescribing antineoplastic agents and 2 studies addressed pharmacovigilance and risk management byassessing treatment- related adverse effects. Chemotherapy, target therapy, and immunotherapy have different toxicityprofiles. Strategies for systemic antineoplastic treatment prescription safety, such as early detection and monitoringof associated adverse events, help to minimize the damage caused by adverse reactions. A multidisciplinary approachis important to recognize, report and manage the risk of treatment. The evidence from the studies included in thisintegrative review suggests that assessment of treatment-related adverse events as well as risk management strategiesshould be considered to improve the quality and safety of the systemic antineoplastic treatment.

Keywords: Antineoplastic agents, Immunotherapy, Drug-related side effects and adverse reactions, Patient safety